Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3820-3826

  Ma, Wanlong ^a   Kantarjian, Hagop ^b   Bekele, Benjamin ^b   Donahue, Amber C ^a   Zhang, Xi ^a   Zhang, Zhong J ^a   O'Brien, Susan ^b   Estey, Elihu ^b   Estrov, Zeev ^b   Cortes, Jorge ^b   Keating, Michael ^b   Giles, Francis ^c   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CASPASE; CHYMOTRYPSIN; PROTEASOME; TRYPSIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; UREA NITROGEN BLOOD LEVEL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASPASES; CHYMOTRYPSIN; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; RISK FACTORS; SURVIVAL ANALYSIS; TRYPSIN; YOUNG ADULT;

EID: 66649101365     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3034     Document Type: Article

References (27)

1. Bullinger L, Döhner K, Bair E, et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-1616 (Pubitemid 38501163)
2. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin- proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996;10:1979-1990 (Pubitemid 26346107)
3. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 2006;145:676-684 (Pubitemid 46768844)
4. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996;56:2649-2654
5. Tatebe H, Yanagida M. Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2. Curr Biol 2000;10:1329-1338
6. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-847 (Pubitemid 26255262)
7. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992;61:761-807.
8. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-771 (Pubitemid 24294452)
9. Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007;109:2100-2105 (Pubitemid 46348211)
10. Ma W, Kantarjian H, O'Brien S, et al. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 2008;112:1306-1312
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br JCancer 1977;35:1-39.
13. Cox DR. Regression models and life tables. JR Stat Soc 1972;34:187-220.
14. Schulgen G, Lausen B, Olsen JH, Schumacher M. Outcome-oriented cutpoints in analysis of quantitative exposures. Am J Epidemiol 1994;140:172-184 (Pubitemid 24205814)
15. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771 (Pubitemid 28259189)
16. Giles FJ, Albitar M. Plasma-based testing as a new paradigm for clinical testing in hematologic diseases. Expert Rev Mol Diagn 2007;7:615-623 (Pubitemid 47547726)
17. Rogers A, Joe Y, Manshouri T, et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 2004;103:801-818 (Pubitemid 38393040)
18. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507-2513 (Pubitemid 36857605)
19. Ahmed M, Giles F, Joe Y, et al. Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. Eur J Haematol 2003;71:174-178 (Pubitemid 37082839)
20. Jilani I, Estey E, Manshuri T, et al. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia 2003;17:114-119 (Pubitemid 36175895)
21. Ma W, Kantarjian H, Jilani I, et al. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia 2006;20:1989-1991 (Pubitemid 44614888)
22. Ma W, Kantarjian H, Zhang X, et al. Higher detection rate of JAK2 mutation using plasma. Blood 2008;111:3906-3907
23. Jilani I, Kantarjian H, Faraji H, et al. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res 2008;32:936-943
24. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-448
25. Mrózek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology (Am Soc Hematol Educ Prog) 2006;169-177
26. + immature phenotype. Haematologica 2008;93:57-66.
27. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008;14:1446-1454